Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?

Dermata Therapeutics Inc. (NASDAQ:DRMA) shares jumped 27.78% to $1.38 in the pre-market session on Wednesday after the San Diego-based company reported second-quarter results for the period ended Jun. 30 on Tuesday.

Earnings per share came in at -$0.74, missing the analyst estimate of -$0.55 by 34.5%.

Cash Runway Tightens Into Q4

According to the company, it held $4.4 million in cash as of Jun. 30, down from $7.5 million at year-end, citing $4.9 million used in operations. Dermata said existing funds should be sufficient to fund operations into the fourth quarter of 2026.

Research and development spending fell to $0.2 million as resources shifted toward commercialization, while selling, general and administrative expenses rose to $2.8 million on marketing and legal costs.

Skincare Launch on the Horizon

Dermata said it is preparing to launch its first commercial product, Tome Foundational Treatment, on Aug. 25. The product is designed as a once-weekly application meant to serve as the base of a skincare routine and renew the skin’s appearance.

CEO Gerry Proehl said, “Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company.” He added that the launch positions the company to “begin generating revenues in the near future while continuing to build long-term value for our shareholders.”

Trading Metrics, Technical Analysis

Dermata Therapeutics has a market capitalization of $4.34 million, with a 52-week high of $6.58 and a 52-week low of $0.95.

The Relative Strength Index (RSI) for DRMA is 37.32.

Over the past 12 months, the small-cap stock has dropped 82.32%.

DRMA is currently trading near its 52-week low.

Price Action: The stock closed Tuesday’s regular session at $1.08, down 3.57%, according to Benzinga Pro data.

Benzinga’s Edge Stock Rankings indicate DRMA stock has a negative price trend across all time frames.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Gorodenkoff on Shutterstock.com